Literature DB >> 11371397

The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States.

M S Schechter1, B J Shelton, P A Margolis, S C Fitzsimmons.   

Abstract

There is considerable variability in the clinical course of disease in cystic fibrosis (CF). Although currently unidentified modifier genes might explain some of this heterogeneity, other factors are probably contributory. Socioeconomic status (SES) is an important predictor of health status in many chronic polygenic diseases, but its role in CF has not been systematically evaluated. We performed a historical cohort analysis of pediatric CF patients in the United States using National Cystic Fibrosis Foundation Patient Registry (NCFPR) data for 1986 to 1994, and used Medicaid status as a proxy for low SES. The adjusted risk of death was 3.65 times higher (95% confidence interval [CI]: 3.03 to 4.40) for Medicaid patients than for those not receiving Medicaid. The percent predicted FEV(1) of surviving Medicaid patients was less by 9.1% (95% CI: 6.9 to 11.2). Medicaid patients were 2.19 times more likely to be below the 5th percentile for weight (95% CI: 1.91 to 2.51) and 2.22 times more likely to be below the 5th percentile for height (95% CI: 1.95 to 2.52) than were non-Medicaid patients. Medicaid patients were 1.60 times more likely to require treatment for a pulmonary exacerbation (95% CI: 1.29 to 1.98). There was no difference in the number of outpatient clinic visits for Medicaid and non-Medicaid patients. We conclude that low SES is associated with significantly poorer outcomes in children with CF. Barriers in access to specialty health care do not seem to explain this difference. Further study is indicated to determine what adverse environmental factors might cluster in CF patients of low SES to cause worse outcomes.

Entities:  

Mesh:

Year:  2001        PMID: 11371397     DOI: 10.1164/ajrccm.163.6.9912100

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  96 in total

1.  Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function.

Authors:  J Michael Collaco; Scott M Blackman; John McGready; Kathleen M Naughton; Garry R Cutting
Journal:  J Pediatr       Date:  2010-06-30       Impact factor: 4.406

Review 2.  Strategies for identifying modifier genes in cystic fibrosis.

Authors:  Michael P Boyle
Journal:  Proc Am Thorac Soc       Date:  2007-01

3.  Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.

Authors:  Meghan E McGarry; John M Neuhaus; Dennis W Nielson; Esteban Burchard; Ngoc P Ly
Journal:  Pediatr Pulmonol       Date:  2017-10-30

4.  Marked improvement in cystic fibrosis lung disease and nutrition following change in home environment.

Authors:  Atul Gupta; Donald Urquhart; Mark Rosenthal
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

5.  Neighborhood income, health insurance, and prehospital delay for myocardial infarction: the atherosclerosis risk in communities study.

Authors:  Randi E Foraker; Kathryn M Rose; Aileen P McGinn; Chirayath M Suchindran; David C Goff; Eric A Whitsel; Joy L Wood; Wayne D Rosamond
Journal:  Arch Intern Med       Date:  2008-09-22

6.  Cat and dog exposure and respiratory morbidities in cystic fibrosis.

Authors:  Christopher B Morrow; Karen S Raraigh; Deanna M Green; Scott M Blackman; Garry R Cutting; Joseph M Collaco
Journal:  J Pediatr       Date:  2014-07-12       Impact factor: 4.406

Review 7.  Update in Cystic Fibrosis 2018.

Authors:  Bonnie W Ramsey; Gregory P Downey; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2019-05-15       Impact factor: 21.405

8.  Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.

Authors:  Michael S Schechter; Susanna A McColley; Stefanie Silva; Tmirah Haselkorn; Michael W Konstan; Jeffrey S Wagener
Journal:  J Pediatr       Date:  2009-07-16       Impact factor: 4.406

9.  Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.

Authors:  Don B Sanders; Julia Emerson; Clement L Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Ann Am Thorac Soc       Date:  2015-08

10.  Vitamin D and bone health in adults with cystic fibrosis.

Authors:  Linda L Wolfenden; Suzanne E Judd; Reshma Shah; Rupan Sanyal; Thomas R Ziegler; Vin Tangpricha
Journal:  Clin Endocrinol (Oxf)       Date:  2008-02-11       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.